©2024 Stanford Medicine
Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
Not Recruiting
Trial ID: NCT05463822
Purpose
Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral
medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into
the detrusor muscle of the bladder. However, the traditional procedure requires a cystoscope
inserted into the bladder which can be painful and is associated with a risk of urinary tract
infection. The purpose of this study is to determine if transvaginal injection of BTA into
the detrusor muscle of the bladder wall is feasible to perform, and efficacious for the
treatment of refractory overactive bladder.
Official Title
Feasibility and Efficacy of Transvaginal Botulinum Toxin A Chemodenervation of the Bladder for the Third Line Treatment of Refractory Overactive Bladder
Stanford Investigator(s)
Amy D. Dobberfuhl, MD, MS
Assistant Professor of Urology
Eligibility
Inclusion Criteria:
- Females with overactive bladder
- Females who are considering intradetrusor botulinum toxin A chemodenervation for the
treatment of refractory overactive bladder
Exclusion Criteria:
- Overactive bladder caused by neurological condition (i.e. spinal cord injury, multiple
sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, etc.)
- Predominance of stress urinary incontinence as reported by the patient
- Involvement in other studies with potentially overlapping indications or symptoms
- Patients who are unable to undergo a transvaginal ultrasound intervention as a result
of anatomic barriers or discomfort will be excluded from enrollment
- Patients known to be pregnant or breastfeeding
- Known allergy to botulinum toxin A injection therapy
Intervention(s):
drug: Transvaginal botulinum toxin A (BTA) injection
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305